Background {#Sec1}
==========

Smokeless tobacco (SLT) consists of a number of products containing tobacco, which are consumed---without burning---through the mouth or nose \[[@CR1]\]. A diverse range of SLT products are available worldwide, varying in their composition, methods of preparation and consumption, and associated health risks (Table [1](#Tab1){ref-type="table"}) \[[@CR1]\]. Its use is most prevalent in South and South-East Asia where one-third of tobacco is consumed in smokeless form \[[@CR2], [@CR3]\]. Wrapped in a betel leaf with areca nut, slaked lime, and catechu, SLT is often served at social occasions in this region. Other products (e.g. gutkha, khaini) contain slaked lime, areca nut, flavourings, and aromatic substances \[[@CR4]\]. A number of products based on powdered tobacco (e.g. snus) are also consumed in Nordic countries and North America. In other parts of world, the most commonly used SLT products (Table [1](#Tab1){ref-type="table"}) include Chimó (Venezuela), Nass (Uzbekistan, Kyrgyzstan), Tambook (Sudan, Chad), and Snuff (Nigeria, Ghana, South Africa).Table 1Smokeless tobacco products consumed most commonly across the worldSmokeless tobacco productsRegions (WHO)Countries (highest consumption)Other ingredientsPreparation and usepH^a^Nicotine^a^ (mg/g)Total TSNA^a^ (ng/g)Snus (Swedish)Europe (Region A)Nordic countries (Denmark, Finland, Iceland, Norway, Sweden)Water, sodium carbonate, sodium chloride, moisturisers, flavouringA heat treatment process; placed between the gum and upper lip6.6--7.27.8--15.2601--723Plug, Snuff (US), Snus (US)Americas (Region A and B)US, Canada, MexicoSweeteners, liquoricePlug; air cured4.7--7.83.9--40.1313--76,500Dry or moist snuff; finely ground and fire curedSnus; steam curedSnuff; kept between lip and gum, dry snuff can be inhaled tooChimóAmericas (Region B)Venezuela, ColombiaSodium bicarbonate, brown sugar, Mamo'n tree ashesTobacco paste made from tobacco leaves; placed between the lip or cheek and gum and left there for some time6.9--9.45.3--30.19390Nass (Naswar)Europe (Region B) and Eastern Mediterranean (Region D)Uzbekistan, Kyrgyzstan, Tajikistan, Afghanistan, Pakistan, IranLime, ash, flavourings (cardamom), indigoSundried and powdered; placed between lip or cheek and gum8.4--9.18.9--14.2478--1380TambookEastern Mediterranean (Region D) and Africa (Region D)Sudan, ChadMixed with moist sodium bicarbonateFermented and grounded; placed and kept in mouth7.3--10.19.6--28.2302,000--992,000Snuff (North and West African)Africa (Region D)Nigeria, Ghana, Algeria, Cameroon, Chad, SenegalDried tobacco leaves mixed with potassium nitrate and other saltsDry snuff; finely ground and inhaled as a pinch9.0--9.42.5--7.41520--2420Moist snuff is placed in mouthSnuff (South African)Africa (Region E)South AfricaDried tobacco leaves mixed with ashDry snuff; finely ground and inhaled as a pinch6.5--10.11.2--17.21710--20,500KhainiSouth East Asia (Regions B and D) Western Pacific (Region B) Eastern Mediterranean (Region D) Europe (Region A)India, Bangladesh, Nepal, BhutanSlaked lime, menthol, flavourings, areca nutShredded; kept in mouth between lips and gum9.6--9.82.5--4.821,600--23,900ZardaBangladesh, India, Pakistan, Myanmar, Thailand, Indonesia, Nepal, Maldives, Sri Lanka, UKServed wrapped in a betel leaf with lime, catechu, areca nutsShredded tobacco leaves are boiled with lime and saffron; the mixture is dried then chewed and spat5.2--6.59.5--30.45490--53,700GutkhaIndia, Pakistan, Bangladesh, Nepal, Myanmar, Sri Lanka, UKBetel nut, catechu, flavourings, sweetenersCommercially manufactured; sucked, chewed, and spat7.4--8.90.2--4.283--23,900*WHO* World Health Organization, *TSNA* tobacco-specific nitrosamines^a^Figures are adapted from Stanfill et al. \[[@CR6]\], Lawler et al. \[[@CR17]\], and NIH & CDC 2014 report on smokeless tobacco products \[[@CR37]\]

In addition to nicotine, SLT products contain over 30 carcinogens \[[@CR5]\] including tobacco-specific nitrosamines (TSNA), arsenic, beryllium, cadmium, nickel, chromium, nitrite, and nitrate. The level of nicotine and carcinogens vary between products (Table [1](#Tab1){ref-type="table"}) \[[@CR6]\]. For example, nicotine content among SLT products varies between 0.2 and 40.1 mg/g, compared to commercial filtered cigarettes which contain 16.3 mg/g of nicotine \[[@CR7]\]. Their pH also varies, which, being a key determinant of the level of absorption of nicotine and carcinogens, determines its toxicity: the higher the pH, the higher the absorption and, consequently, the higher the toxicity \[[@CR6]\]. Such considerations mean that there are substantial variations between different SLT products in the level of risk posed to human health \[[@CR4], [@CR8]--[@CR11]\]. It is therefore important not to consider SLT as a single product, but rather as groups of products with differences in their toxicity and addictiveness depending upon their carcinogen, nicotine, and pH levels. The diversity in SLT toxicity has been an impediment not only in establishing its global risks to human health, but also in agreeing on international policies for its prevention and control. It is therefore perhaps unsurprising that despite several country-specific studies \[[@CR12]--[@CR15]\] no attempt has hitherto been made to estimate its global disease burden.

To overcome these challenges, we developed a novel approach to estimate the global burden associated with the use of SLT products. The determinants of their toxicity (carcinogens and pH) and addictiveness (nicotine) are dependent on preparation methods, ingredients that are added to SLT products, and consumption behaviours. Given that the SLT preparations and consumption patterns are determined by, and vary with, geography and culture \[[@CR16]\], it is possible to group them according to their availability in different parts of the world (Table [1](#Tab1){ref-type="table"}). These groups of SLT products, classified according to different geographical regions, will also be distinguishable from each other on the basis of their toxicity, addictiveness, and associated health risks. Hence, the risks were assumed to be highest in those regions and cultures where products are combined with other ingredients, and are prepared and consumed in a way that makes them very alkaline (i.e. a high pH), and rich in nicotine and TSNA \[[@CR6], [@CR17]\]. Building on this assumption, we aimed to estimate the worldwide burden of disease attributable to SLT use, measured in terms of disability adjusted life years (DALYs) lost and number of deaths in 2010.

Methods {#Sec2}
=======

We used the comparative risk assessment method, which evaluates changes in population health (burden of disease) that result from modifying a population's exposure to a risk factor \[[@CR18], [@CR19]\]. For this, we used 2010 datasets, which provided the most recent global estimates of burden of disease \[[@CR20]\]. The estimates were calculated for individual countries and then grouped into 14 World Health Organization (WHO) sub-regions (Additional file [1](#MOESM1){ref-type="media"}: Appendix 1) \[[@CR21]\]. These were generated through estimating the following:The prevalence of SLT consumptionDiseases caused by SLT useThe relative risks of acquiring these diseasesThe population attributable fraction (PAF) for each of these diseasesThe overall burden of these diseases in terms of DALYs lost and deathsProportion of this burden attributable to SLT use

Prevalence of smokeless tobacco use {#Sec3}
-----------------------------------

We carried out a systematic literature search (see Additional file [1](#MOESM1){ref-type="media"}: Appendix 2 for a detailed description of the methods employed) for the point prevalence (current use) of SLT consumption among all adult (≥15 years) populations, and also for men and women separately. Only one prevalence report was included for one country. Latest national prevalence data collected as part of an international or regional survey were preferred over an older isolated national or a sub-national survey. We used data from the Global Adult Tobacco Survey (GATS), where available \[[@CR22]\]. In its absence, other international (WHO STEPwise approach to Surveillance, The Demographic and Health Surveys), regional (Special Europe Barometer), national, and/or sub-national surveys were used to extract prevalence data.

Diseases caused by smokeless tobacco use {#Sec4}
----------------------------------------

A scoping review was carried out to identify associated diseases. A series of focused literature reviews were subsequently carried out to find and assess the evidence of causation between each of these diseases and SLT use. Our search strategies and selection criteria are provided in Additional file [1](#MOESM1){ref-type="media"}: Appendix 3. One researcher ran the searches, which were then independently scrutinised by another independent researcher who considered the search results against the pre-specified inclusion and exclusion criteria. Similarly, one researcher extracted data, which were independently crosschecked by another researcher. In particular, we appraised the studies for case definitions for diseases and for assessment methods for measuring exposure to SLT and for investigating the effects of potential confounders. We excluded those diseases (and respective studies) where evidence was not supportive of a causal relationship. Only studies that adequately controlled for smoking and/or alcohol as potential confounders either at the design or the analysis stage were carried forward into the next stage of the analysis (discussed below). Quality was assessed using the Newcastle-Ottawa Scale for assessing the quality of non-randomised studies in meta-analyses \[[@CR23]\].

Assessing risk and meta-analyses {#Sec5}
--------------------------------

Risk estimates (relative risks/odds ratios) and their confidence intervals (CI) were log transformed to produce effect sizes and standard errors, respectively \[[@CR24]\]. We carried out random effects meta-analysis using RevMan version 5 to estimate pooled risk estimates. We first obtained country-specific risk estimates (relative risks/odds ratios) for individual diseases by pooling data from the included studies carried out in respective countries. We then extrapolated non-specific global risk estimates by pooling respective country-specific risk estimates. We were mindful that the risk of acquiring diseases varies between countries owing to differences in SLT products used. Therefore, for each disease where good country-specific risk estimates (pooled estimate from a meta-analysis of three or more studies in respective country) were available, we applied these to respective countries and also to those countries and regions where similar SLT products are used. In the absence of good country-specific risk estimates, we used either one of the following two approaches: (a) In countries and regions that use SLT products with moderate to high pH and TSNAs levels, we applied non-specific global estimates (pooled estimate from a meta-analysis of all studies); and (b) in countries and regions where there was either no information available on the SLT products or the information available indicates low levels of pH and TSNA, we did not apply any estimates. Further details on the application of these assumptions across all 14 WHO regions are provided in web Additional file [1](#MOESM1){ref-type="media"}: Appendix 4. We only used those pooled relative risks (country or non-specific) that were found to be statistically significant.

Where associations were presented for more than one SLT product in the same paper, we considered these as separate studies for the purpose of meta-analysis. Similarly, where risks were given separately for former and current SLT users, these were also treated as separate studies. We did not attempt to group risks according to gender because very few studies had such sub-group analysis.

Population attributable fraction {#Sec6}
--------------------------------

PAF is the proportional reduction in disease or mortality that would occur if exposure were reduced to zero \[[@CR25], [@CR26]\]. PAF was estimated for each disease for each country for both males and females, using the following formula:$$\documentclass[12pt]{minimal}
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Overall burden {#Sec7}
--------------

The overall number of DALYs and deaths for each associated disease for both males and females for each country were extracted from the 2010 Global Burden of Disease study \[[@CR27], [@CR28]\].

Attributable burden {#Sec8}
-------------------

The attributable burden (AB), in deaths and DALYs, was estimated for each associated disease for each country for both males and females by multiplying PAF by the overall burden of the disease (B):$$\documentclass[12pt]{minimal}
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Results {#Sec9}
=======

Prevalence of smokeless tobacco use {#Sec10}
-----------------------------------

We found adult prevalence figures for SLT consumption in 115 countries (Fig. [1](#Fig1){ref-type="fig"}). The definition for 'adult' ranged from 15, 16, 25, or 35 years at one end to 49, 64, 65, 70, 74, 84, 85, 89, or no age limit at the other. The PRISMA diagram describing the selection of the prevalence reports is provided in Additional file [1](#MOESM1){ref-type="media"}: Appendix 5a.Fig. 1Smokeless tobacco prevalence among males and females

In general, SLT consumption was higher among males than females (Table [2](#Tab2){ref-type="table"}). Mauritania had the highest prevalence of SLT consumption among females (28.3 %), followed by Bangladesh (27.9 %), Madagascar (19.6 %), India (18.4 %), and Bhutan (17.3 %). Among males, Myanmar (51.4 %), Nepal (37.9 %), India (32.9 %), Uzbekistan (31.8 %), and Bangladesh (26.4 %) had the highest consumption rates. Within Europe, SLT (snus) consumption was high in Sweden (24.0 % males, 7.0 % females) and Norway (20.0 % males, 6.0 % females).Table 2Prevalence of smokeless tobacco use in different countries of the world according to WHO sub-regional classificationWHO sub-regionsCountryMFSourceYearAfrica (Region D)Algeria210.4STEPS \[[@CR38]\]2005Benin12.75.7STEPS \[[@CR38]\]2008Burkina Faso--3.86DHS \[[@CR39]\]2011Cameroon1.940.94DHS \[[@CR39]\]2011Cape Verde3.55.8STEPS \[[@CR38]\]2007Chad1.90.4STEPS \[[@CR38]\]2008Comoros7.722.99DHS \[[@CR39]\]2012Gabon0.480.34DHS \[[@CR39]\]2012Gambia0.81.4STEPS \[[@CR38]\]2010Ghana1.330.2DHS \[[@CR39]\]2008Guinea1.41.5STEPS \[[@CR38]\]2009Liberia2.32.4DHS \[[@CR40]\]2007Madagascar24.6619.6DHS \[[@CR39]\]2009Mali51.2STEPS \[[@CR38]\]2007Mauritania5.728.3STEPS \[[@CR38]\]2006Niger4.552.3DHS \[[@CR39]\]2012Nigeria3.20.5DHS \[[@CR40]\]2008Sao Tome & Principe3.81.9STEPS \[[@CR38]\]2009Senegal6.630.23DHS \[[@CR39]\]2011Sierra Leone312STEPS \[[@CR38]\]2009Togo5.12.2STEPS \[[@CR38]\]2010Africa (Region E)Botswana7.214.5STEPS \[[@CR38]\]2007Burundi0.030.31DHS \[[@CR39]\]2011Congo (Brazzaville)8.31.54DHS \[[@CR39]\]2012Congo (Republic)8.673.22DHS \[[@CR39]\]2013Cote d\'Ivoire0.611.27DHS \[[@CR39]\]2012Eritrea5.80.2STEPS \[[@CR38]\]2004Ethiopia1.940.2DHS \[[@CR39]\]2011Kenya2.051.29DHS \[[@CR39]\]2008Lesotho1.39.1DHS \[[@CR40]\]2009Malawi1.95STEPS \[[@CR38]\]2009Mozambique10.940.82DHS \[[@CR39]\]2011Namibia1.82.3DHS \[[@CR40]\]2006--07Rwanda5.82.73DHS \[[@CR39]\]2011South Africa2.410.9DHS \[[@CR41]\]2003Swaziland2.60.8STEPS \[[@CR38]\]2007Tanzania2.030.83DHS \[[@CR39]\]2010Uganda2.941.5DHS \[[@CR39]\]2011Zambia0.31.2DHS \[[@CR39]\]2007Zimbabwe1.60.4DHS \[[@CR41]\]2011Americas (Region A)Canada2--ICS \[[@CR41]\]2011USA6.50.4ICS \[[@CR41]\]2010Americas (Region B)Argentina0.10.2GATS \[[@CR42]\]2012Barbados00.6STEPS \[[@CR38]\]2007Brazil0.60.3GATS \[[@CR42]\]2010Dominican Republic1.90.3DHS \[[@CR40]\]2007Grenada2.20.3STEPS \[[@CR38]\]2011Mexico0.30.3GATS \[[@CR42]\]2009Paraguay31.6ICS \[[@CR41]\]2011St Kitts & Nevis^a^0.30.1STEPS \[[@CR38]\]2007Trinidad & Tobago0.50.3STEPS \[[@CR38]\]2011Venezuela6.20.9ICS \[[@CR41]\]2011Americas (Region D)Haiti--2.5DHS \[[@CR40]\]2005--06Eastern Mediterranean (Region B)Libya2.20.1STEPS \[[@CR38]\]2009Saudi Arabia1.30.5STEPS \[[@CR38]\]2004Tunisia8.62.2ICS \[[@CR41]\]2005--06Eastern Mediterranean (Region D)Egypt4.80.3GATS \[[@CR42]\]2009Iraq1.60.3STEPS \[[@CR38]\]2006Pakistan16.32.44DHS \[[@CR43]\]2012--13Sudan24.11STEPS \[[@CR38]\]2005Yemen15.16.2ICS \[[@CR41]\]2003Europe (Region A)Austria7.81.1SEBS \[[@CR44]\]2012Belgium1.10.6SEBS \[[@CR44]\]2012Cyprus2.10.4SEBS \[[@CR44]\]2012Czech Republic2.50.4SEBS \[[@CR44]\]2012Denmark31ICS \[[@CR41]\]2010Finland5.50.3ICS \[[@CR41]\]2011France1.20.6SEBS \[[@CR44]\]2012Germany3.43.4SEBS \[[@CR44]\]2012Iceland5.97--ICS \[[@CR41]\]2008Ireland2.20.9SEBS \[[@CR44]\]2012Italy1.81.5SEBS \[[@CR44]\]2012Luxembourg1.81SEBS \[[@CR44]\]2012Malta5.51.5SEBS \[[@CR44]\]2012Netherlands0.30.1ICS \[[@CR41]\]2011Norway206ICS \[[@CR41]\]2011Portugal4.41.1SEBS \[[@CR44]\]2012Slovenia1.80.4SEBS \[[@CR44]\]2012Spain0.40.2SEBS \[[@CR44]\]2012Sweden247ICS \[[@CR41]\]2011Switzerland41.3ICS \[[@CR41]\]2011United Kingdom1.60.5SEBS \[[@CR44]\]2012Europe (Region B)Ajerbaijan0.30DHS \[[@CR40]\]2006Armenia1.80DHS \[[@CR40]\]2005Bulgaria0.30SEBS \[[@CR44]\]2012Georgia10.2ICS \[[@CR41]\]2010Kyrgyzstan70.3ICS \[[@CR41]\]2006Poland10.1GATS \[[@CR42]\]2009Romania0.40.2GATS \[[@CR42]\]2011Slovakia3.90.7SEBS \[[@CR44]\]2012Uzbekistan31.80.2DHS \[[@CR40]\]2002Europe (Region C)Latvia5.80.9ICS \[[@CR41]\]2010Lithuania1.20.2SEBS \[[@CR44]\]2012Moldova0.10DHS \[[@CR40]\]2005Russia10.2GATS \[[@CR42]\]2009Ukraine0.50GATS \[[@CR42]\]2010South East Asia (Region B)Indonesia1.52GATS \[[@CR42]\]2011Sri Lanka24.96.9STEPS \[[@CR38]\]2006Thailand1.15.2GATS \[[@CR42]\]2011South East Asia (Region D)Bangladesh26.427.9GATS \[[@CR42]\]2009Bhutan21.117.3STEPS \[[@CR38]\]2007India32.918.4GATS \[[@CR42]\]2009Maldives5.62.6STEPS \[[@CR38]\]2011Myanmar51.416.1STEPS \[[@CR38]\]2009Nepal37.96DHS \[[@CR41]\]2011Timor Leste2.481.93DHS \[[@CR43]\]2009--10Western Pacific (Region A)Australia0.750.41ICS \[[@CR45]\]2004Western Pacific (Region B)Cambodia2.214.8STEPS \[[@CR38]\]2010China0.70GATS \[[@CR42]\]2010Lao People's Democratic Republic14.61.1STEPS \[[@CR38]\]2008Malaysia0.90.6GATS \[[@CR42]\]2011Micronesia22.43STEPS \[[@CR38]\]2002Mongolia2.80.5STEPS \[[@CR38]\]2009Philippines2.81.2GATS \[[@CR42]\]2009Vietnam0.32.3GATS \[[@CR42]\]2010*DHS* The Demographic and Health Surveys, *ICS* Individual Country Survey, *GATS* Global Adult Tobacco Survey, *SEBS* The Special Europe Barometer Survey, *STEPS* STEPwise approach to Surveillance^a^Populations of St Kitts and Nevis are tiny and unlikely to affect our estimates

Diseases caused by smokeless tobacco use {#Sec11}
----------------------------------------

The initial scoping review identified a number of associated diseases, including a range of cancers, cardiovascular diseases (ischaemic heart disease and stroke), periodontal conditions, and adverse pregnancy outcomes. The subsequent more focused systematic reviews identified 53 studies (Table [3](#Tab3){ref-type="table"}) reporting association between SLT consumption and cancers of mouth, pharynx, larynx, oesophagus, lung, and pancreas (39 studies); and cardiovascular diseases, such as ischaemic heart disease and stroke (14 studies). PRISMA flow diagrams describing the selection process of the studies identified in the literature searches are provided in Additional file [1](#MOESM1){ref-type="media"}: Appendix 5b,c. The pooled non-specific relative risks were statistically significant for cancers of the mouth, pharynx, and oesophagus (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, and [5](#Fig5){ref-type="fig"}). Only statistically significant relative risks (country*-*specific or non-specific) were included in the model to estimate attributable risks. For example, the pooled non-specific relative risk for laryngeal cancer was 1.42 (95 % CI 0.77--2.59), and hence excluded (Additional file [1](#MOESM1){ref-type="media"}: Appendix 6). Likewise, none of the country-specific estimates for the USA were statistically significant (Additional file [1](#MOESM1){ref-type="media"}: Appendix 4). Based on the above reviews, we assumed that a causal association exists between some SLT products and cancers of the mouth, pharynx, and oesophagus, and ischaemic heart disease.Table 3Smokeless tobacco use and risk of cancers, ischaemic heart disease, and stroke---studies included in meta-analysisCountryStudy periodStudy designExposure statusInclusion of cigarette/alcohol usersOutcomeOdds ratios/relative risks (95 % confidence intervals)CommentsQuality assessment (NOS)^a^ReferenceCANCERSIndia2001--2004Case--controlSmokeless tobacco with or without additivesNo/NoOral cancer0.49 (0.32--0.75)Exclusive SLT usersSelection\*\*\*\*Anantharaman et al. 2007 \[[@CR46]\]Comparability\*\*Exposure/Outcome\*India1996--1999Case--controlEver SLT usersYes/YesOral cancer7.31 (3.79--14.1)Never drinkers adjusted for smokingSelection\*\*\*\*Balaram et al. 2002 \[[@CR47]\]9.19 (4.38--19.28)Never smokers adjusted for alcoholComparability\*\*Exposure/Outcome \*India1982--1992Case--controlTobacco quid chewingYes/NoOral cancer5.8 (3.6--9.34)Adjusted for smokingSelection\*\*\*Dikshit & Kanhere 2000 \[[@CR48]\]Pharyngeal cancer1.2 (0.8--1.8)Comparability\*Lung cancer0.7 (0.4--1.22)Exposure/Outcome\*IndiaUnclearCase--controlChewing tobaccoNo/NoOral cancer10.75 (6.58--17.56)Exclusive SLT usersSelection\*\*Goud et al. 1990 \[[@CR49]\]Comparability\*Exposure/Outcome^0^India1990--1997CohortCurrent SLT usersNo/NoOral cancer5.5 (3.3--9.17)Exclusive SLT usersSelection\*\*\*\*Jayalekshmi et al. 2009 \[[@CR50]\]Former SLT users9.2 (4.6--18.40)Comparability\*Exposure/Outcome\*\*India1990--1997CohortCurrent SLT userYes/YesOral cancer2.4 (1.7--3.39)Adjusted for smoking and alcoholSelection\*\*\*\*Jayalekshmi et al. 2010 \[[@CR51]\]Former SLT users2.1 (1.3--3.39)Comparability\*Exposure/Outcome\*\*\*IndiaMay 2005Case--controlEver SLT usersNo/NoOral cancer4.23 (3.11--5.75)Exclusive SLT usersSelection\*\*\*Jayant et al. 1977 \[[@CR52]\]Pharyngeal cancer2.42 (1.74--3.37)Comparability\*\*Laryngeal cancer2.8 (2.07--3.79)Exposure/Outcome^0^Oesophageal cancer1.55 (1.15--2.07)India1968Case--controlTobaccoYes/NoOral cancer4.63 (3.50--6.14)Exclusive chewers and non-chewers data availableSelection\*\*\*Jussawalla & Deshpande 1971 \[[@CR53]\]Pharyngeal cancer3.09 (2.31--4.13)Comparability\*\*Laryngeal cancer2.29 (1.72--3.05)Exposure/Outcome^0^Oesophageal cancer3.82 (2.84--5.13)India2005--2006Case--controlTobacco flakesYes/YesOral cancer7.6 (4.9--11.79)Adjusted for smoking and alcoholSelection\*\*\*\*Madani et al. 2010 \[[@CR54]\]Gutkha12.7 (7--23.04)Comparability\*\*Mishiri3.0 (1.9--4.74)Exposure/Outcome\*IndiaUnclearCase--controlChewing tobaccoYes/YesOral cancer5.0 (3.6--6.94)Adjusted for smoking and alcoholSelection\*\*\*\*Muwonge et al. 2008 \[[@CR55]\]Comparability\*Exposure/Outcome\*India1982--1984Case--controlChewing tobaccoYes/NoOral cancer10.2 (2.6--40.02)Adjusted for smokingSelection\*\*\*Nandakumar et al. 1990 \[[@CR56]\]Comparability\*\*Exposure/Outcome\*India1980--1984Case--controlSLT usersNo/NoOral cancer1.99 (1.41--2.81)Exclusive SLT usersSelection\*\*Rao et al. 1994 \[[@CR57]\]Comparability^0^Exposure/Outcome\*India1952--1954Case--controlChewing tobaccoNo/NoOral cancer4.85 (2.32--10.14)Exclusive SLT usersSelection\*\*\*Sanghvi et al. 1955 \[[@CR58]\]Pharyngeal cancer2.02 (0.94--4.33)Comparability\*\*Laryngeal cancer0.76 (0.37--1.56)Exposure/Outcome^0^India1983--1984Case--controlSnuff (males only)Yes/YesOral cancer2.93 (0.98--8.76)Adjusted for smoking and alcohol; adjusted effect size is only among malesSelection\*\*\*Sankaranarayan et al. 1990 \[[@CR59]\]Comparability^0^Exposure/Outcome\*IndiaNot givenCase--controlTobacco chewingYes/YesOropharyngeal cancer7.98 (4.11--13.58)^b^Adjusted for smoking and alcoholSelection\*\*\*Wasnik et al. 1998 \[[@CR60]\]Comparability\*\*Exposure/Outcome^0^India1991--2003Case--controlChewing tobaccoNo/NoOral cancer5.88 (3.66--7.93)Exclusive SLT usersSelection\*\*\*\*Subapriya e al. 2007 \[[@CR61]\]Comparability\*\*Exposure/Outcome\*\*India1950--1962Case--controlTobacco with or without paan or limeYes/NoOral and oropharyngeal cancer41.90 (34.20--51.33)Exclusive chewer data availableSelection\*\*Wahi et al. 1965 \[[@CR62]\]Note: data of habit was not available for the whole cohortComparability\*\*Exposure/Outcome^0^Pakistan1996--1998Case--controlNaswarYes/YesOral cancer9.53 (1.73--52.50)Adjusted for smoking and alcoholSelection\*\*\*Merchant et al. 2000 \[[@CR63]\]Paan with tobacco8.42 (2.31--30.69)Comparability\*\*Exposure/Outcome\*Sweden1973--2002CohortSnusYes/YesOral and pharyngeal combined3.10 (1.50--6.41)Adjusted for smoking and alcoholSelection\*\*Roosar et al. 2008 \[[@CR64]\]Comparability\*\*Outcome\*\*\*India1993--1999Case--controlChewing tobaccoYes/YesOral cancer5.05 (4.26--5.99)Adjusted for smoking and alcoholSelection\*\*\*Znaor et al. 2003 \[[@CR65]\]Pharynx1.83 (1.43--2.34)Comparability\*\*Oesophagus2.06 (1.62--2.62)Exposure/Outcome\*Norway1966--2001CohortChewing tobacco plus oral snuffNo/NoOral cancer1.1 (0.5--2.42)Adjusted for smoking, might be confounded by alcohol useSelection\*\*\*Bofetta et al. 2005 \[[@CR66]\]Oesophageal cancer1.4 (0.61--3.21)Comparability\*Pancreatic cancer1.67 (1.12--2.49)Exposure/Outcome\*\*\*Lung cancer0.80 (0.61--1.05)Sweden1988--1991Case--controlOral snuffYes/YesOral cancer1.4 (0.8--2.45)Adjusted for smoking and alcoholSelection\*\*Lewin et al. 1998 \[[@CR67]\]Larynx0.9 (0.5--1.62)Comparability\*\*Oesophagus1.2 (0.7--2.06)Exposure/Outcome\*Pharynx0.7 (0.4--1.22)Sweden1969--1992CohortSnusNo/NoOral cancer0.8 (0.4--1.60)Exclusive SLT usersSelection\*\*\*Luo et al. 2007 \[[@CR68]\]Lung cancer0.8 (0.5--1.28)Comparability\*Pancreatic cancer2 (1.20--3.33)Exposure/Outcome\*\*\*Sweden2000--2004Case--controlOral snuffYes/YesOral0.70 (0.3--1.63)Adjusted for smoking and alcoholSelection\*\*\*Rosenquist et al 2005 \[[@CR69]\]Comparability\*\*Exposure/Outcome\*\*Sweden1980--1989Case--controlOral snuffYes/YesOral cancer0.8 (0.5--1.28)Adjusted for smoking and alcoholSelection\*\*Schildt et al. 1998 \[[@CR70]\]Comparability\*\*Exposure/Outcome\*\*\*USA1972--1983Case--controlOral snuffYes/YesOral cancer0.8 (0.4--1.60)Not clear if adjusted for smoking and alcoholSelection\*\*Mashberg et al. 1993 \[[@CR71]\]Chewing tobacco1 (0.7--1.43)Comparability^0^Exposure/Outcome\*USANot givenCase--controlSLT useYes/YesOral cancer0.90 (0.38--2.13)Adjusted for smoking and alcoholSelection\*\*\*Zhou et al. 2013 \[[@CR15]\]Pharyngeal cancer1.59 (0.84--3.01)Comparability\*\*Laryngeal cancer0.67 (0.19--2.36)Exposure/Outcome\*India2001--2004Case--controlChewing tobaccoNo/NoPharyngeal cancer3.18 (1.92--5.27)Exclusive SLT usersSelection\*\*\*Sapkota et al. 2007 \[[@CR72]\]Laryngeal cancer0.95 (0.52--1.74)Comparability\*\*Exposure/Outcome\*Pakistan1998--2002Case--controlSnuff dippingNo/NoOesophageal cancer4.1 (1.3--12.93)Adjusted for areca nutSelection\*\*\*Akhtar et al. 2012 \[[@CR73]\]Quid with tobacco14.2 (6.4--31.50)Comparability\*\*Exposure/Outcome\*\*India2008--2012Case--controlNass chewingNo/NoOesophageal cancer2.88 (2.06--4.03)Exclusive SLT usersSelection\*\*\*Dar et al. 2012 \[[@CR74]\]Gutkha chewing2.87 (0.87--9.47)Comparability\*\*Exposure/Outcome\*\*India2007--2011Case--controlOral snuffYes/YesOesophageal cancer3.86 (2.46--6.06)Adjusted for smoking and alcoholSelection\*\*Sehgal et al. 2012 \[[@CR75]\]Comparability\*\*Exposure/Outcome\*India2011--2012Case--controlChewing tobaccoYes/YesOesophageal cancer2.63 (1.53--4.52)Adjusted for smoking and alcoholSelection\*\*\*Talukdar et al. 2013 \[[@CR76]\]Comparability\*\*Exposure/Outcome\*Sweden1995--1997Case--controlOral snuffYes/YesOesophageal cancer (adenocarcinoma)1.2 (0.7--2.06)Adjusted for smoking and alcoholSelection\*\*\*Lagergren et al. 2000 \[[@CR77]\](Squamous cell carcinoma)1.4 (0.9--2.18)Comparability\*\*Exposure/Outcome\*Sweden1969--1993CohortOral snuffYes/NoOesophageal cancer (Adenocarcinoma)1.3 (0.8--2.11)Adjusted for smokingSelection\*\*Zendehdel et al. 2008 \[[@CR78]\](Squamous cell carcinoma)1.2 (0.8--1.80)Comparability\*Exposure/Outcome\*\*Sweden1974--1985CohortSLT usersNo/NALung cancer0.90 (0.20-- 4.05)Adjusted for age, region of originSelection\*\*\*Bolinder et al. 1994 \[[@CR79]\]Comparability\*Outcome\*\*Morocco1996--1998Case--controlSLT usersYes/NoLung cancer1.05 (0.28--3.94)Adjusted for smokingSelection\*\*Sasco et al. 2002 \[[@CR80]\]Comparability\*\*Exposure/Outcome\*\*USA1977--1984Case--controlSLT usersYes/NoOesophageal cancer1.2 (0.1--14.40)Adjusted for smokingSelection\*\*\*Brown et al. 1988 \[[@CR81]\]Comparability\*\*Exposure/Outcome\*\*USA1986--1989Case--controlSLT usersYes/NoPancreatic cancer1.4 (0.5--3.92)Adjusted for smokingSelection\*\*\*Alguacil & Silverman 2004 \[[@CR82]\]Comparability\*Exposure/Outcome\*\*USA2000--2006Case--controlChewing tobaccoYes/YesPancreatic cancer0.6 (0.3--1.20)Adjusted for smoking and alcoholSelection\*\*\*\*Hassan et al. 2007 \[[@CR83]\]Oral snuff0.5 (0.1--2.5)Comparability\*\*Exposure/Outcome\*CARDIOVASCULAR DISEASES (ischaemic heart disease and stroke)52 countries1999--2003Case--controlChewing tobaccoNo/YesMyocardial infarction1.57 (1.24--1.99)Adjusted for diabetes, abdominal obesity, hypertension, exercise, dietSelection\*\*\*\*Teo et al. 2006 \[[@CR29]\]Comparability\*\*Exposure/Outcome\*Pakistan2005--2011Case--controlDippers only (Naswar)No/NAMyocardial infarction1.46 (1.20--1.77)Adjusted for age, sex, region, ethnicitySelection\*\*\*\*Alexander 2013 \[[@CR84]\]Chewers only (Paan/ Supari/ Gutkha)1.71 (1.46--2.00)Comparability\*\*Exposure/Outcome\*\*Bangladesh2006--2007Case--controlEver SLT usersNo/NAMyocardial infarction, Angina pectoris2.8 (1.1--7.13)Adjusted for age, sex, hypertensionSelection\*\*\*Rahman & Zaman 2008 \[[@CR85]\]Comparability\*\*Exposure/Outcome\*Bangladesh2010Case--controlEver SLT usersNo/NAMyocardial infarction, Angina pectoris0.77 (0.52--1.14)Adjusted for age, hypertension, diabetes, acute psycho-social stressSelection\*\*\*\*Rahman et al. 2012 \[[@CR86]\]Comparability\*\*Exposure/Outcome\*Sweden1998--2005Case--controlCurrent SLT usersNo/NAMyocardial infarction0.73 (0.35--1.52)Exclusive SLT usersSelection\*\*\*Hergens et al. 2005 \[[@CR87]\]Former SLT users1.2 (0.46--3.13)Comparability\*\*Exposure/Outcome\*\*Sweden1978--2004CohortEver SLT usersNo/NAMyocardial infarction0.99 (0.90--1.10)Adjusted for age, BMI, region of residenceSelection\*\*Hergens et al. 2007 \[[@CR88]\]Comparability\*\*Exposure/Outcome\*\*\*Sweden1989--1991Case--controlRegular SLT usersYes/NAMyocardial infarction1.01 (0.66--1.55)^c^Adjusted for age, education, smokingSelection\*\*\*Huhtasaari et al. 1992 \[[@CR89]\]Comparability\*\*Exposure/Outcome\*Sweden1991--1993Case--controlFormer SLT usersNo/NAMyocardial infarction1.23 (0.54--2.82)Exclusive SLT usersSelection\*\*\*\*Huhtasaari et al. 1999 \[[@CR90]\]Comparability\*\*Exposure/Outcome\*\*Sweden1988--2000CohortDaily SLT usersNo/NAIschaemic heart disease1.41 (0.61--3.28)Adjusted for BMI, physical activity, diabetes, hypertensionSelection\*\*\*\*Johansson et al. 2005 \[[@CR91]\]Comparability\*\*Exposure/Outcome\*\*Sweden1985--1999Case--controlCurrent SLT usersNo/NAMyocardial infarction0.82 (0.46--1.46)Adjusted for BMI, physical activity, education, cholesterolSelection\*\*\*\*Wennberg et al. 2007 \[[@CR92]\]Former SLT users0.66 (0.32--1.36)Comparability\*\*Exposure/Outcome\*\*Sweden1985--2000Case--controlRegular SLT usersNo/NAStroke0.87 (0.41--1.83)Adjusted for diabetes, hypertension, education, marital status, cholesterolSelection\*\*\*\*Asplund et al. 2003 \[[@CR93]\]Comparability\*\*Exposure/Outcome\*\*Sweden1978--2003CohortEver SLT usersNo/NAStroke1.02 (0.92--1.13)Adjusted for age, BMI, region of residenceSelection\*\*Hergens et al. 2008 \[[@CR94]\]Comparability\*\*Exposure/Outcome\*\*\*Sweden1998--2005CohortCurrent SLT usersNo/NAIschaemic heart disease0.85 (0.51--1.42)Adjusted for age, hypertension, diabetes, cholesterolSelection\*\*\*Hansson et al. 2009 \[[@CR95]\]Former SLT usersStroke1.07 (0.56--2.04)Comparability\*\*1.18 (0.67--2.08)Exposure/Outcome\*\*1.35 (0.65--2.82)Sweden1991--2004CohortSLT usersNo/NAMyocardial infarction0.75 (0.3--1.87)Adjusted for age, diabetes, occupation, hypertension, physical activity, BMI, marital statusSelection\*\*\*Janzon et al. 2009 \[[@CR96]\]Stroke0.59 (0.2--1.5)Comparability\*\*Exposure/Outcome\*\**BMI* body mass index, *NA* not applicable, *NOS* Newcastle-Ottawa Scale, *SLT* smokeless tobacco^a^NOS for assessing the quality of non-randomised studies in meta-analyses based on selection, comparability, and exposure/outcome. Number of stars (\*) indicates the number of criteria met for each of these three categories \[[@CR23]\]^b^Effect sizes are for oral and pharyngeal cancers combined and were included in the meta-analysis for oral cancer only^c^Based on parameter estimate and standard error reported in paperFig. 2Random effects model showing relative risk for mouth cancer for smokeless tobacco useFig. 3Random effects model showing relative risk for pharyngeal cancer for smokeless tobacco useFig. 4Random effects model showing relative risk for oesophageal cancer for smokeless tobacco useFig. 5Random effects model showing relative risk for ischaemic heart disease for smokeless tobacco use

Relative risks {#Sec12}
--------------

Based on 32 studies, the estimated pooled non-specific relative risk for mouth (oral cavity, tongue, and lip) cancers was 3.43 (95 % CI 2.26--5.19) (Fig. [2](#Fig2){ref-type="fig"}). Studies from South-East Asia indicated an increased risk of oral cancer for SLT use whereas results from studies pertaining to Europe and the Americas did not substantiate such an association. For cancers of the pharynx, pooled non-specific relative risk was 2.23 (95 % CI 1.55--3.20), based on ten studies (Fig. [3](#Fig3){ref-type="fig"}). For oesophageal cancers, no clear increased risk was present in studies in the USA, whereas a pooled estimate reported a relative risk of 2.17 (95 % CI 1.70--2.78) (Fig. [4](#Fig4){ref-type="fig"}). For ischaemic heart disease, no good country-specific risk estimates were available (Fig. [5](#Fig5){ref-type="fig"}). However, we found one large case--control study (INTERHEART study) \[[@CR29]\] conducted in 52 countries from all regions showing a statistically significant risk of ischaemic heart disease (adjusted odds ratio 1.57, 95 % CI 1.24--1.99) among SLT users.

Applying risk estimates {#Sec13}
-----------------------

For cancers in general, pooled country-specific risk estimates obtained from Sweden and the USA were applied to Europe A and Americas A, respectively. For South-East Asia B and D and Western Pacific B regions, country-specific estimates from India were applied. There were a few exceptions to this rule, because some countries (UK, Mexico, Pakistan, China, Mongolia) differed in their SLT consumption patterns from their respective regions (see Additional file [1](#MOESM1){ref-type="media"}: Appendix 4 for details). In short, country-specific risk estimates for cancers could only be fully applied to five regions. For the remaining nine regions, our findings were imputed either by applying statistically significant non-specific risk estimates or none at all (Additional file [1](#MOESM1){ref-type="media"}: Appendix 4). In case of ischaemic heart disease, Sweden was the only country with a pooled country-specific relative risk (0.98, 95 % CI 0.90--1.07) obtained from a good number (more than three) of studies. For 11 out of 14 regions, we used a large multi-country study (INTERHEART)---conducted in 52 countries---to apply and deduce risk estimates. The three regions (Europe A and C and Americas D) were excluded, as these were not among those regions included in the INTERHEART study (Additional file [1](#MOESM1){ref-type="media"}: Appendix 4). There was one exception (UK) where INTERHEART study estimates were applied because SLT products consumed in the UK commonly originate from South Asia.

Attributable burden {#Sec14}
-------------------

The attributable burden of SLT use is outlined in Table [4](#Tab4){ref-type="table"}. Our estimates indicate that in 2010, SLT use led to 1,711,539 DALYs lost and 62,283 deaths due to cancers of mouth, pharynx, and oesophagus, and, based on data from the benchmark 52 country INTERHEART study, 4,725,381 DALYs lost and 204,309 deaths from ischaemic heart disease. In total, SLT use caused the loss of 6,436,920 DALYs and 266,592 deaths. The figures show that three-quarters of these deaths and loss of DALYs were among males. This disease burden was found to be distributed across all WHO sub-regions. However, nearly 85 % of the total burden attributable to SLT use was in South-East Asia, with India alone accounting for 74 % of the global burden, followed by Bangladesh (5 %).Table 4Number of DALYs lost and deaths from SLT use in 2010, by WHO sub-region as defined in Additional file [1](#MOESM1){ref-type="media"}: Appendix 1WHO sub-regions^a^Mouth cancerPharyngeal cancerOesophageal cancerIschaemic heart diseaseAll causesMFAllMFAllMFAllMFAllMFAllDEATHSAfrica D863612315217157772332323751307425818663448Africa E1558524019123138925264112029232125176512723037Americas A00000000010,24064910,88910,24064910,889Americas B901110228331749831030291132112223141536Americas D000000000000000Eastern Mediterranean B111121024154417451545776534Eastern Mediterranean D93325411876045966310121291141740192683279950136811,318Europe A66137816218244382825391456848651971062Europe B14631485715826022625506156566259691626130Europe C000000000000000South-East Asia B43839683512958187243139382320518525057401624456461South-East Asia D11,527645917,98712,715348516,20015,247562520,873117,52345,047162,570157,01360,617217,630Western Pacific A00000000069361046936104Western Pacific B134159293223456516311431678143981337410704443Worldwide13,586741821,00313,608365617,26417,680633624,016152,64751,662204,309197,52069,072266,592DALYsAfrica D2516104635624526551741191906602464,04319,11683,15971,13022,13293,262Africa E49262293722057334992210,159629016,44933,50221,10954,61049,15930,04279,201Americas A000000000172,2067213179,419172,2067213179,419Americas B23112302541734637971717176189322,252472826,98027,014519732,210Americas D000000000000000Eastern Mediterranean B285363213394386201069841138311,22410,246144811,694Eastern Mediterranean D29,240766936,90916,446180018,24727,777361331,390187,39421,544208,938260,85734,627295,483Europe A15142241738369454144949545549483971491988815,230230417,534Europe B443960449917042017246460566517115,6401991117,631128,2432128130,371Europe C000000000000000South-East Asia B10,968774118,70932171487470456082983859166,96929,91396,88186,76242,124128,886South-East Asia D351,752179,051530,803338,976107,041446,017400,770143,146543,916290,6993938,5283,845,5213,998,4911,367,7665,366,257Western Pacific A0000000001024340136410243401364Western Pacific B370035677267615794140913131485279772,93616,83089,76678,56422,675101,239Worldwide411,652201,918613,569363,120111,673474,793462,957160,219623,1773,661,1951,064,1864,725,3814,898,9241,537,9966,436,920

Discussion {#Sec15}
==========

We have found that SLT is consumed worldwide and that its use results in substantial, potentially avoidable, morbidity and mortality. However, owing to marked differences in the types of products available, patterns of consumption, and associated risks, there are substantial differences in the attributable burden between regions and countries. In particular, SLT consumption in South-East Asia leads to a much greater burden of disease than in Sweden, despite its use being equally prevalent. This is due to the much lower levels of TSNA and pH in SLT products in Sweden compared to those found in SLT in South-East Asia \[[@CR6]\]. Similarly, SLT products used in the USA have lower risk estimates than for those used in South-East Asia.

We found that more than six million DALYs were lost and over a quarter of a million deaths occurred in 2010 owing to SLT consumption. However, our estimates require cautious interpretation because of a number of potential limitations.

First, our analysis was limited to those countries and diseases for which reliable prevalence and risk data were available, respectively. Most global tobacco surveys that reported on SLT consumption did not include all countries in the world. While global figures on smoking prevalence were available, we did not find any SLT prevalence figures for almost half of all countries. Where SLT prevalence figures were available, two countries (Micronesia and Saint Kitts & Nevis) were excluded from the final estimates owing to an absence of data for cancers in the 2010 Global Burden of Disease study. Moreover, for certain disease outcomes, e.g. adverse reproductive and oral health effects, poor quality as well as limited quantity of evidence precluded their inclusion.

Second, lack of country-specific risk estimates leads to considerable uncertainty. Despite several countries reporting SLT consumption, most did not have any reliable information on the types of SLT products used and on their associated health risks. For example, studies from several African countries reported high SLT consumption (Table [2](#Tab2){ref-type="table"}), but provided little information on their hazard profile. There is some evidence, mainly from Sudan \[[@CR30]\], that products used in Africa tend to have a higher pH than those used in Europe or in the USA. However, we did not find any data on the risks associated with widespread SLT use in southern parts of Africa. Likewise, various forms of SLT have been used in parts of South America (Brazilian rapê or Venezuelan chimó) for many years, yet there are no studies on the health effects of such products. In the absence of country-specific risk estimates, we assumed that in general those populations that consume similar SLT products are likely to share similar health risks and susceptibilities. We extrapolated and applied risk estimates to most countries included in our analysis on that basis (Additional file [1](#MOESM1){ref-type="media"}: Appendix 4). For cancer, our extrapolation was based on estimates obtained from several studies; for ischaemic heart diseases, extrapolations were mostly based on a single although large multi-country study (INTERHEART). As a result, almost three-quarters of the estimated SLT disease burden, which is attributed to ischaemic heart disease, is uncertain. Therefore, a cautious interpretation would be to exclude ischaemic heart disease burden figures from our estimates. However, in estimating these figures we had already excluded those regions and their respective countries that were not included in INTERHEART study. As a pointer on future research, our study highlights the need to study risk of SLT consumption on ischaemic heart diseases across the spectrum of SLT products and consumption behaviours. In time, this will produce more country-specific risk estimates, which would undoubtedly improve the reliability of our estimates presented here.

Third, the disease burden observed in 2010 is unlikely to be a consequence of SLT consumption in recent years. Therefore, our prevalence figures, obtained in surveys carried out in the last decade and used in the estimates, could be problematic. However, we assumed that the SLT consumption rates have remained stable over the last 30--40 years in these countries. We consider this as a safe assumption given that SLT use is not a new trend and historically embedded in culture and tradition in many countries, most remarkably in South Asia \[[@CR31]\]. Consumption trends based on repeated youth surveys in India and Bangladesh suggest that SLT use has remained stable over the last decade \[[@CR32]\]. Evidence from Sweden suggests that while more people are using snus now than 25 years ago, the consumption trends, compared to cigarette use, have essentially remained stable in this period \[[@CR33], [@CR34]\].

Finally, the age range of the adult sampling frames used in different SLT prevalence surveys varied, which could also increase uncertainty. The main difference between two of the key categories used was in the adult range starting from either ≥15 years or ≥25 years. Given that the risk of cancers and ischemic heart disease accumulates after many years of use well beyond young adult age, it may not have made much of a difference to our burden of disease estimates.

For the seven countries in South-East Asia region D, we estimated that 55,060 deaths caused by cancers of mouth, pharynx, and oesophagus, could be attributed to SLT in 2010. This is a little higher than the estimates from a recent study in which 50,000 deaths were attributed to SLT in eight South Asian countries \[[@CR4]\]. This discrepancy may be explained by the fact that we used the most recent, updated prevalence and burden of disease figures.

Our estimate does not include economic impact. However, given the nature of the associated diseases, it is likely that the SLT use imposes a huge economic burden on weak health systems and poor economies. Moreover, owing to higher consumption of SLT among people of lower socio-economic status and inequitable access to health care in low-income and middle-income countries, its use is likely to contribute to driving disadvantaged sections of these societies into further poverty. A disproportionate impact on the male population (more than 70 % of disease burden due to SLT is in males) is also likely to have a disproportionate economic impact on societies in terms of reduced workforce contributions by men. On the other hand, effective legislation, policy, and preventive programmes could avert this burden due to SLT.

The signatories of the WHO's Framework Convention on Tobacco Control should, in addition to the focus on reducing smoking consumption and related harm, now also consider the need to regulate production, marketing, and labelling of SLT products. This is particularly necessary in those countries where prevalence is high and SLT products are manufactured at a large scale without any checks on the carcinogenic level of their ingredients \[[@CR35]\]. In countries where its use is largely limited to immigrant populations (such as in the UK) \[[@CR36]\], strict regulation and taxation policies should be enforced which prevent import of SLT products and sale by local shops.

SLT is an important health issue, applying to a large part of the world. The data presented here are the most comprehensive gathered and brought together thus far. However, considerable uncertainties remain pertaining to risk estimation of different diseases associated with SLT use. Therefore more research is needed to investigate the newly established and previously known adverse health outcomes pertaining to SLT, particularly within countries where prevalence is high but no research evidence of risk estimation is available. Moreover, more descriptive questions about the type of SLT products and the pattern of use should be introduced into national surveys and publications of such findings encompassing all the regions.

Conclusions {#Sec16}
===========

Our study, a first attempt to assess global burden of disease due to SLT, estimates that more than six million DALYs are lost and over a quarter of a million deaths occur each year owing to its consumption. There is a need to build on the insights obtained from efforts to reduce cigarette smoking-related harm and to investigate strategies to reduce use of SLT and decrease the substantial associated burden of harm.
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===============

Additional file 1:**Supplementary description of methods and results sections.** (DOCX 281 kb)
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